NDC 31260-402 - SUCRALFATE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 31260-402
- Package NDCs from labels
- 31260-402-01, 31260-402-02
- Manufacturer
- Gulbrandsen Technologies India Private Limited
- Effective date
- 2026-04-03
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| SUCRALFATE - Gulbrandsen Technologies India Private Limited | Gulbrandsen Technologies India Private Limited | 2026-04-03 | BULK INGREDIENT - ANIMAL DRUG |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 31260-402-01 | SUCRALFATE | 25 kg in 1 DRUM | POWDER | 25 | 3 | |
| 31260-402-02 | SUCRALFATE | 0.5 kg in 1 CONTAINER | POWDER | 0.5 | 3 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sucralfate | SUCRALFATE | Preferred Pharmaceuticals Inc. | 536b8c00-13ab-4397-a754-63a1c92bf883 | 2026-09-02 | Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | VistaPharm, LLC | cbfbe146-5d42-4a55-9050-df2b5581487a | 2026-09-02 | Warnings, Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Preferred Pharmaceuticals Inc. | 5ec71444-cc55-47bd-8abc-b3cfc3b47d8e | 2026-09-01 | Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Chartwell RX, LLC | 37aee721-b9c7-4e6b-a1a1-e826d8541d6b | 2026-08-27 | Warnings, Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Zydus Lifesciences Limited | 882b7596-f62c-4be2-8f67-e64310718baa | 2026-08-08 | Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Viona Pharmaceuticals Inc | c708201b-2618-4470-a3ff-8ecf04d6b3a0 | 2026-08-08 | Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Cardinal Health 107, LLC | 444a743a-4843-4b33-bad5-3dfc1fb2d004 | 2026-07-29 | Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Safecor Health, LLC | 526f6ebc-557c-4c53-8118-1907baa0820a | 2026-07-16 | Warnings, Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Cardinal Health 107, LLC | 1eb38f64-4d5a-46e6-a030-057beece5e44 | 2026-07-10 | Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Chartwell RX, LLC | 30c0965a-02a0-46b5-aa09-3f5fb5047b22 | 2026-07-06 | Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | NCS HealthCare of KY, LLC dba Vangard Labs | 3b0259fa-806f-44c1-8deb-c11dbd84582d | 2026-06-24 | Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | ASCLEMED USA INC. | cd25eb96-29ea-48b2-bdee-c2ea98f216b8 | 2026-05-18 | Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Safecor Health LLC | 1a6d96f2-fe1f-4aaf-8520-616973c224aa | 2026-04-07 | Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Cardinal Health 107, LLC | 92c8672a-c6b8-4ec8-a815-c30bdd960ac7 | 2026-03-30 | Warnings, Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | PAI Holdings, LLC dba PAI Pharma | 113a068a-2ce9-421c-8b89-87ce30e19225 | 2026-03-11 | Warnings, Adverse reactions | XX73205DH5 |
| sucralfate | SUCRALFATE | Strides Pharma Science Limited | 8e25bff2-769e-4bd4-a6de-895c58b840d2 | 2026-03-10 | Warnings, Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE ORAL SUSPENSION | Major Pharmaceuticals | 98a8fedd-fa06-416a-8a85-b899631978f9 | 2026-02-11 | Warnings, Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | Preferred Pharmaceuticals Inc | a434bf8f-cc60-4d84-a9a4-61c3ff6b700e | 2026-01-21 | Adverse reactions | XX73205DH5 |
| Sucralfate | SUCRALFATE | AvKARE | 0909acc5-c746-17fb-e063-6394a90a677f | 2026-01-19 | Adverse reactions | XX73205DH5 |
| Sucralfate oral suspension | SUCRALFATE | Glenmark Pharmaceuticals Inc., USA | 1e595c2a-edd0-43f7-a2db-69553b9557d9 | 2026-01-06 | Warnings, Adverse reactions | XX73205DH5 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.